Ovarian Cancer pp 783-792 | Cite as
p53 Adenovirus as Gene Therapy for Ovarian Cancer
- 869 Downloads
Abstract
Ovarian cancer arises from the accumulation of mutations in multiple combinations of genes (1). The most extensively studied tumor suppressor gene in solid tumors is p53, a 53-kD nuclear phosphoprotein that binds DNA. The p53 gene product plays a role in normal cellular proliferation by regulating gene transcription, cell cycle control, and apoptosis (2). Mutations of p53 are the most common molecular genetic abnormality to be described in human cancer, and have been identified in malignancies of the breast, colon, lung, esophagus, head and neck, and hematopoietic system (3). Mutations of the p53 gene have been identified in 30 to 79% of epithelial ovarian cancers (4,5). Most of the mutations identified in p53 are distributed throughout the open reading frame as missense mutations. We have identified a missense mutation in the p53 gene in the 2774 ovarian cancer cell line that converts an arginine residue in the DNA binding region of the protein to a histidine residue (6). The mutation in codon 273 we found in 2774 cells is one of the six major hotspots identified for p53 missense mutations (7).
Keywords
Ovarian Cancer Epithelial Ovarian Cancer Ovarian Cancer Cell Ovarian Cancer Cell Line Peritoneal WashingReferences
- 1.Bast, R. C. Jr., Boyer, C. M., Jacobs, I., Xu, F. J., Wu, S., Wiener, J., et al. (1993) Cell growth regulation on epithelial ovarian cancer. Cancer 71, 1597–1601.PubMedGoogle Scholar
- 2.Harris, C. C. and Hollstein M. (1993) Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329, 1318–1327.CrossRefPubMedGoogle Scholar
- 3.Crystal, R. G. (1995) Transfer of genes to humans: early lessons and obstacles to success. Science 270, 404–410.CrossRefPubMedGoogle Scholar
- 4.Kohler, M. F., Marks, J. R., Wiseman, R. W., Davidoff, A. M., Clarke-Pearson, D. L., Soper, J. T., et al. (1993) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer Inst. 85, 1513–1519.CrossRefPubMedGoogle Scholar
- 5.Kupryjnszyk, J., Thor, A., Beauchamp, R., Merrit, V., Edgerton, S. M., Bell, D. A., et al. (1993) P53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA 90, 4961–4965.CrossRefGoogle Scholar
- 6.Santoso, J. T., Tang, D. C., Lane, S. B., Hung, J., Reed, D. S., Muller, C. Y., et al. (1995) Adenovirus-based p53 gene therapy in ovarian cancer. Gynecolog. Oncol. 69, 197–204.Google Scholar
- 7.Levine, A. J., Perry, M. E., Chang, A., Silver, A., Dittmer, D., Wu, M., et al. (1994) The 1993 Walter Hubert Lecture: the role of the p53 tumorsuppressor gene in tumorigenesis. Brit. J. Cancer 69, 409–416.CrossRefPubMedGoogle Scholar
- 8.Fujiwara, T., Grimm, E. A., and Roth, J. A. (1994) Gene therapeutics and gene therapy for cancer. Curr. Opin. Oncol. 6, 96–105.CrossRefPubMedGoogle Scholar
- 9.Mulligan, R. C. (1993) The basic science of gene therapy. Science 260, 926–932.CrossRefPubMedGoogle Scholar
- 10.Harris, C. C. and Hollstein, M. (1993) Clinical implications of the p53 tumor-suppressor gene. N.Engl. JMed. 329, 1318.CrossRefGoogle Scholar
- 11.Von Greunigan, V. R., Santoso, J. T., Lane, S. B., Miller, D. S., and Mathis, J. M. (1998) Adenovirus-mediated p53 gene therapy for ovarian cancer. Gynecolog. Oncol., in press.Google Scholar
- 12.Von Greunigan, V. R., O’Boyle, J. D., Coleman, R. A., Miller, D. S., and Mathis, J. M. (1999) Safety and efficacy of intraperitoneal adenovirus-mediated p53 gene therapy for ovarian cancer. Int. J. Gynecolog. Cancer, 9, 365–372.CrossRefGoogle Scholar
- 13.Cai, D. W., Mukhopadhyay, T., Liu, Y., Fujiwara, T., Roth, J. A. (1993) Stable expression of the wild-type p53 gene in human lung cancer cells after retro virus-mediated gene transfer. Hum. Gene Ther. 4, 617–624.CrossRefPubMedGoogle Scholar
- 14.Tang, D. C., Johnston, S. A., and Carbone, D. P. (1994) Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther. 1, 15–20.PubMedGoogle Scholar
- 15.Dvoretsky, P. M., Richards, K. A., Angel, C., Rabinowitz, L., Stoler, M. H., Beecham, J. B., et al. (1998) Distribution of disease at autopsy in 100 women with ovarian cancer. Hum. Pathol. 9, 57–63.Google Scholar
- 16.Mittereder, N., March, K. L., and Trapnell, B. C. (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498–7509.PubMedGoogle Scholar
- 17.Graham, F. L. and Prevoc, L. (1991) Manipulation of adenovirus vectors, in Methods in Molecular Medicine Vol 7: Gene Transfer and Expression Protocols (Murray, E. J. ed.), Humana Press, Clifton, NJ, pp. 109–128.Google Scholar
- 18.Yamamoto, R. S., Kobayashi, M., Plunkett, J. M., Masunaka, I. K., Orr, S. L., and Granger, G. A. (1985) Production and detection of lymphotoxin in vitro: micro-assay for lymphotoxin, in Investigation of Cell-Mediated Immunity (Yoshido, T. ed.), Churchill Livingston, New York, pp. 126–134.Google Scholar
- 19.Gorman, A. M., Samali, A., McGowan, A. J., and Cotter, T. G. (1997) Use of flow cytometry techniques in studying mechanisms of apoptosis in leukemic cells. Cytometry 29, 97–105.CrossRefPubMedGoogle Scholar
- 20.Joseph, A., Ingelfinger, F., and Mosteller, J. H. (1993) Biostatistics in Clinical Medicine, 3rd Ed. McGraw-Hill, New York.Google Scholar
- 21.Tsai, C. M., Gazdar, A. F., Venzon, D. J., Steinberg, S. M., Dedrick, R. L., Mulshine, J. L., et al. (1989) Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). Cancer Res. 49, 2390–2397.PubMedGoogle Scholar